All News

18F-rhPSMA-7.3 Exhibits Greater Ability to Upstage Disease Vs Conventional Imagine in Recurrent Prostate Cancer
May 16, 2022

Superior post-scan disease upstaging in patients with recurrent prostate cancer was observed with 18F-rhPSMA-7.3 compared with conventional baseline imaging.

CT-Based Waist Skeletal Muscle Volume May Have Prognostic Value in Endometrial Cancer
May 16, 2022

Patients with endometrial cancer who have low volumetric skeletal muscle measurements had lower 3-year overall and progression-free survival rates.

First-Line Nivolumab/Ipilimumab Fails to Improve OS Vs Chemotherapy in PD-L1–Low Unresectable or Metastatic Urothelial Carcinoma
May 16, 2022

Patients with untreated unresectable or metastatic urothelial carcinoma and PD-L1 expression of 1% or more who received treatment with nivolumab and ipilimumab in the first-line setting did not experience an improved overall survival vs those getting standard-of-care chemotherapy, according to a final analysis of a phase 3 trial.

Deciding Which Cancer-Related Fatigue Assessment Tool to Use Just Got Much Easier
May 16, 2022

Lisa Sprod, PhD, MPH, provides perspective on a cancer-related fatigue assessment tools.

Cancer-Related Fatigue Outcome Measures in Integrative Oncology: Evidence for Practice and Research Recommendations
May 16, 2022

This review article written by Danielle Gentile, PhD, et al, reviews the management of cancer-related fatigue in integrative oncology.

David M. O’Malley, MD, Talks Next Steps for Treatment in Endometrial Cancer
May 16, 2022

David M. O’Malley, MD, spoke about where the future of treatment is heading for patients with endometrial cancer.

Recap: Treatment Advances in Chronic GVHD
May 15, 2022

A panel of experts in stem cell transplant and cellular immunotherapy builds a lively discussion on current and emerging treatment options for the management of acute and chronic graft versus host disease.

Shortened Adjuvant CAPOX Treatment Does Not Compromise Safety, Efficacy in Stage III Colon Cancer
May 14, 2022

The phase 3 ACHIEVE trial analyzed Asian patients with stage III colon cancer to determine how a 3-month treatment duration with capecitabine and oxaliplatin compared with 6 months.

Alina Markova, MD, on the Rationale for Assessing Topical Ruxolitinib in Cutaneous Chronic GVHD
May 13, 2022

Alina Markova, MD, discusses the rationale for assessing topical ruxolitinib INCB018424 phosphate 1.5% cream in patients with non-sclerotic and superficially sclerotic chronic cutaneous graft-versus-host disease.

Adolescent and Young Adult ALL and AML Survivors Exhibit Worse Long-Term Survival vs General Population
May 13, 2022

Leukemia survivors who were adolescents or young adults had worse long-term survival outcomes vs the general population.